IL-2联合腹腔热灌注化疗治疗恶性腹水临床观察

目的观察IL-2联合腹腔热灌注化疗治疗恶性腹水的近期疗效及不良反应。方法将60例细胞学确诊为恶性腹水的患者随机分成治疗组(n=30)和对照组(n=30),治疗组给予顺铂60 mg/m2腹腔热灌注,IL-2 100IU/d,第2-8天,3周1次,共完成2～4次;对照组仅给予顺铂60 mg/m2腹腔热灌注化疗,同时对比两组治疗效果及记录不良反应。结果治疗组总有效率为57.3%,对照组总有效率为43.3%,无IL-2相关不良反应出现。结论IL-2联合腹腔热灌注化疗治疗恶性腹水效果明显,是一种安全、有效的治疗手段,值得临床推广应用。

Clinical observation of interleukin-2 with hyperthermic intraperitoneal chemoperfusion for treatment of malignant ascites

Objective To investigate the effects of interleukin-2 combined with hyperthermic intraperitoneal chemoperfusion for the treatment of malignant ascites.Methods Sixty cases of malignant ascites were randomly divided into treatment group（n=30） and control group（n=30）.In the treatment group,the patients were treated with cisplatin 60 mg/m 2 in first day and interleukin-2（IL-2） 100 IU/d from the second day to the eighth day every three weeks.In the control group,the patients were treated with cisplatin 60 mg/m 2 only.Therapeutic effect of the two groups was evaluated and the related complication and adverse reaction recorded.Results The effective rate in the treatment group（57.3%） was significantly higher than in the control group（43.3%） and IL-2-related complication and adverse reaction were not found.Conclusions The effect of interleukin-2 combined with hyperthermic intraperitoneal chemoperfusion is better than hyperthermic intraperitoneal chemoperfusion for the treatment of malignant ascites.So it is the safe and high-efficient therapy for malignant ascites.